The U-M Health Rogel Cancer Center's Blood and Marrow Transplantation (BMT) Program offers compassionate care, multidisciplinary collaboration, and the latest research innovations to help severely ill patients whose conditions require that they undergo this highly specialized treatment.
A bone marrow transplant is a procedure to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. More than 200 adult BMT procedures are performed at U-M each year — one of the largest programs in the state. That level of experience means U-M transplant specialists know what to recommend for each transplant candidate, what to expect from each procedure, and how to respond to every challenge that may arise on the transplant journey.
The BMT Program Team is committed to providing world-class care to our patients and their families. Ours is a team approach, with patients and families part of the team (the most important part!). We encourage patients and family members to raise questions and concerns and to play very active roles during the treatment and recovery journey.
Our program's dedicated team of doctors, nurses, physician assistants, and transplant coordinators are specially trained in and solely devoted to stem cell transplantation. Their focus is on performing the procedure safely and effectively; carefully monitoring and caring for patients before, during and after; and communicating with patients' referring physicians throughout the process. The multidisciplinary approach to care means that patients benefit from not just one expert opinion but many. Care plans are personalized to meet the specific needs of each individual patient, and the entire care team meets several times each week to discuss each patient's progress.
The program is accredited by the Foundation for the Accreditation of Hematopoietic Cell Therapy and is also approved by the National Marrow Donor Program and the Southwest Oncology Group.
Behind the growth and success of the BMT Program at Michigan is its commitment to research. Through groundbreaking basic, translational, and clinical research efforts, the University of Michigan has become an international leader in understanding and responding to the particular risks and consequences associated with BMT.
In particular, Rogel Cancer Center researchers are at the forefront of the study and treatment of graft-vs.-host disease (GVHD), one of the most common and dangerous consequences of allogeneic transplantation. Because of this commitment to research, every patient can benefit from the very latest innovations to make transplantation safer and more effective. Please support the BMT program this Giving Blueday, and join us in making advances in transplantation possible!
Donors
View All Donors